JP2005508368A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508368A5
JP2005508368A5 JP2003541772A JP2003541772A JP2005508368A5 JP 2005508368 A5 JP2005508368 A5 JP 2005508368A5 JP 2003541772 A JP2003541772 A JP 2003541772A JP 2003541772 A JP2003541772 A JP 2003541772A JP 2005508368 A5 JP2005508368 A5 JP 2005508368A5
Authority
JP
Japan
Prior art keywords
dosage form
composition
alkyl
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/035900 external-priority patent/WO2003039480A2/en
Publication of JP2005508368A publication Critical patent/JP2005508368A/ja
Publication of JP2005508368A5 publication Critical patent/JP2005508368A5/ja
Pending legal-status Critical Current

Links

JP2003541772A 2001-11-08 2002-11-08 高コレステロール濃度に関連した疾患の治療方法 Pending JP2005508368A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34802001P 2001-11-08 2001-11-08
PCT/US2002/035900 WO2003039480A2 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration

Publications (2)

Publication Number Publication Date
JP2005508368A JP2005508368A (ja) 2005-03-31
JP2005508368A5 true JP2005508368A5 (https=) 2006-01-12

Family

ID=23366328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541772A Pending JP2005508368A (ja) 2001-11-08 2002-11-08 高コレステロール濃度に関連した疾患の治療方法

Country Status (5)

Country Link
EP (1) EP1450816A4 (https=)
JP (1) JP2005508368A (https=)
CA (1) CA2466033A1 (https=)
TW (1) TW200300078A (https=)
WO (1) WO2003039480A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
TW200619191A (en) 2004-10-27 2006-06-16 Sankyo Co Phenyl compounds with more than 2 substitutes
AU2007323998B2 (en) 2006-11-13 2011-09-22 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
EP2459581A4 (en) 2009-07-29 2012-12-26 Univ Chicago LIVER X-RECEPTOR AGONISTS
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
HRP20230747T1 (hr) 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihova uporaba
SMT201800657T1 (it) 2013-03-13 2019-01-11 Sage Therapeutics Inc Steroidi neuroattivi e loro metodi di utilizzo
CN105164161A (zh) * 2013-03-13 2015-12-16 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
JP2016193835A (ja) * 2013-09-04 2016-11-17 学校法人常翔学園 核内受容体肝臓x受容体アゴニスト
PL3639828T3 (pl) 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MX382122B (es) 2015-07-06 2025-03-13 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
PL3319611T3 (pl) 2015-07-06 2021-07-12 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2018009867A1 (en) 2016-07-07 2018-01-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
PT3519422T (pt) 2016-09-30 2022-12-05 Sage Therapeutics Inc Oxisteróis substituídos em c7 e métodos como moduladores nmda
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK4105223T3 (da) 2016-10-18 2025-07-07 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4976857A (https=) * 1972-12-06 1974-07-24
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (ja) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
IL105050A0 (en) * 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
IT1255241B (it) * 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
US7012069B2 (en) * 2001-05-03 2006-03-14 Arch Development Corporation Liver X receptor agonists
IL146223A0 (en) * 1999-04-30 2002-07-25 Arch Dev Corp Steroid derivatives

Similar Documents

Publication Publication Date Title
JP2005508368A5 (https=)
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
HRP20240157T1 (hr) Deuterirani derivati lanifibranora
JP2008522981A5 (https=)
JP2004523581A5 (https=)
HUP0001894A2 (hu) N-Piperidino-3-pirazolkarboxamid-származékot, sóját vagy szolvátját tartalmazó orálisan adagolható gyógyszerkészítmény
JP2007502861A5 (https=)
JP2008509166A5 (https=)
JP2004529125A5 (https=)
JP2003528852A5 (https=)
EP1797878A3 (en) Benzothiazole derivatives
JP2005527576A5 (https=)
JP2004532828A5 (https=)
JP2007505044A5 (https=)
JP2021522327A5 (https=)
JP2009040767A5 (https=)
US20180370960A1 (en) Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apoptosis Protein
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
RU2222537C2 (ru) Новые производные морфолина, способ их получения и содержащие их фармацевтические композиции
US7015238B2 (en) Crystalline organic acid salt of amlodipine
RU2001116601A (ru) Новые производные пиримидина и способы их получения
JP2005516066A5 (https=)
RU2005117626A (ru) Улучшенные готовые лекарственные формы, содержащие замещенные производные имидазола
JP2022501315A5 (https=)
EP2599767A1 (en) Phenylbutyl-derivatives